Decentralized Vaccine Making: A New Path to Fair Access
The COVID‑19 crisis exposed a stark reality: when only a handful of sites can produce vaccines, shortages and delays become inevitable.
In response, 32 research and public health institutions from every continent have united to form the Pasteur Network, a decentralized model that embeds vaccine production within each country’s health system.
How It Works
Local Production
Each participating country turns its research labs into vaccine factories that produce both human and animal shots.Scale & Reach
Twelve facilities already generate more than 525 million doses per year.Community‑Centric Design
Vaccines are tailored to local needs while contributing to global initiatives like CEPI.Integrated Infrastructure
Being part of the national health system keeps production closely aligned with actual demand.
Current Impact
- Human Health – Rapidly deployable vaccines for emerging diseases.
- Animal Health – Prevents zoonotic spillover by vaccinating livestock and wildlife.
- Economic Resilience – Reduces dependence on international supply chains.
Challenges Ahead
| Issue | Details |
|---|---|
| Staff Turnover | High turnover threatens continuity. |
| Funding Stability | Securing long‑term financial support remains difficult. |
| Supply Chains | Fragile logistics can disrupt production. |
| Regulatory Heterogeneity | Different national regulations create complexity. |
| Network Coordination | Ensuring seamless collaboration across 32 institutions can feel disjointed. |
The Takeaway
The Pasteur Network demonstrates that a public‑health‑driven, locally anchored production model can scale globally. It offers a blueprint for future funding strategies, policy frameworks, and international collaboration in vaccine manufacturing.
